LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug Administration (FDA) has authorized marketing of Valeda® Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD), a leading cause of central vision loss in people over 55 in… Continue reading →

Photobiomodulation targets mitochondrial signaling systems to improve cellular bioenergetic processes. Age-related macular degeneration shows mitochondrial dysfunction contributing to disease development and progression. Multiwavelength PBM improved clinical and anatomical outcomes in early-intermediate nonexudative (dry) age-related macular degeneration. Photobiomodulation offers a novel treatment with a unique mechanism and mode of delivery for dry AMD. Read full… Continue reading →

Prevalence of type 1 (T1DM) and type 2 (T2DM) diabetes have reached a state of epidemic highs with the incidence of diabetes increasing at an alarming pace.1–4 Worldwide, diabetes is estimated to affect 463 million people and future estimates suggest an increase to 578 million by the year 2030.1 Diabetes can cause serious sight threatening… Continue reading →

Photobiomodulation (PBM) refers to the process in which wavelengths of light are absorbed by intracellular photoacceptors, resulting in the activation of signaling pathways that culminate in biological changes within the cell. PBM is the result of low-intensity light-induced reactions in the cell in contrast to thermal photoablation produced by high-intensity lasers. PBM has been effectively… Continue reading →

August 07, 2024 06:42 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code effective January 1, 2025. The AMA’s CPT Editorial Panel considered and approved the company’s application for a code to report “Photobiomodulation therapy… Continue reading →

January 16, 2024 07:07 AM Eastern Standard Time SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the… Continue reading →

January 03, 2024 07:12 AM Eastern Standard Time SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the Valeda® Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as… Continue reading →

SEATTLE, Sept. 27, 2023–(BUSINESS WIRE)–LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to… Continue reading →

March 15, 2023 07:17 AM Eastern Daylight Time SEATTLE–(BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda® Light Delivery System.… Continue reading →

SEATTLE, Sept. 15, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, is proud to announce that the AdaptDx Pro® has been recognized as one of Fast Company’s 2022 Innovation and Design Award honorees. This is one of the most sought-after design awards recognizing… Continue reading →

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System

Non-Invasive Treatment of Early Diabetic Macular Edema by Multiwavelength Photobiomodulation with the Valeda Light Delivery System

Photobiomodulation use in ophthalmology – an overview of translational research from bench to bedside

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

LumiThera Announces Fast Company Honors AdaptDx Pro As An Innovation and Design Award Winner